
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics is expected to experience growth in the coming years, with a new avenue for growth outlined in the Los Reyes PEA and fully fundable from current liquidity and Morelos cash flow with a value step up. Although Q2 production came in below estimates, FY2026 guidance was reiterated and Media Luna is on track to deliver first ore before year-end 2026. Additionally, the company's high-quality and high-sensitivity data from the Chromium platform are expected to maintain market share against new entrants, positioning 10x as a premier asset in the genomics space. However, risks include a reduction in adoption and usage momentum due to constrained research funding and increased competition, and the company requires significant investment in R&D and SG&A. Overall, our outlook for 10x Genomics is positive, with an EV/Sales multiple of ~3.5x applied to our 2026 revenue estimate of $618M for a target price of $20/share.
Bears say
10x Genomics is facing a potential dip in instruments sales due to competitors' pricing strategy. The company's Visium platform may also experience a decline in performance due to increased competition. Additionally, the company is heavily reliant on consumable-driven package deals to maintain instrument placements, which may put pressure on average selling prices. Furthermore, the company's push into the translational and clinical space, AI-driven data generation, and extension into CLIA-certified laboratory services may not gain significant uptake and adoption as expected, potentially impacting future revenue growth. These factors, coupled with the company's high operating expenses, suggest a potential decline in profitability in the coming years.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares